☎ 855-698-8887

[email protected]

Our Story: High Quality Data Trumps Big Data

Guardant Health was founded by a group of individuals who thought that next-generation sequencing artfully applied could create fundamental shifts in the quality of healthcare, especially for cancer. They realized that exponential decreases in sequencing costs alone, although seemingly disruptive, were insufficient to help solve problems that have continued to plague cancer care. Using their expertise as pioneers in the fields of digital signal processing, next-generation sequencing and rare genomics, they developed Guardant's core technology with an architecture that could continually maximally leverage any advances in next-generation sequencing and bioinformatics to ensure the highest performance possible today as well as tomorrow.

Our Team

Helmy Eltoukhy, PhD

Chief Executive Officer


AmirAli Talasaz, PhD

President & CTO


  • Expand/Hide Bios

    Helmy is a serial entrepreneur and pioneer in the biotech industry. After receiving his PhD, MS and BS degrees in electrical engineering from Stanford University, he joined the Stanford Genome Technology Center (SGTC) in 2006 to work on low-cost DNA sequencing technologies. At SGTC, he developed the first semiconductor sequencing platform and first base-calling algorithm for next-gen sequencing. In 2007, he co-founded Avantome to commercialize a low-cost, high-performance next-gen sequencing platform to seed the democratization of next-gen sequencing. As its founding CEO, he led Avantome through two rounds of financing and through acquisition by Illumina in 2008. At Illumina, Helmy was Sr Director of Advanced Technology Research, where he developed novel chemistries, hardware and informatics for genetic analysis systems.

    AmirAli is a serial entrepreneur in the sample preparation and clinical research fields. Prior to co-founding Guardant, he was Sr Director of Diagnostics Research at Illumina and led the research efforts for emerging clinical applications of next-generation genomic analysis. During that time, he developed different sample preparation technologies suitable for clinical applications. Before Illumina, he founded Auriphex Biosciences, which focused on purification and genetic analysis of circulating tumor cells for cancer management. The technology was acquired by Illumina in 2009. Prior to his industrial career, he led the Technology Development group at Stanford Genome Technology Center. AmirAli received his PhD in electrical engineering and MSc in management science from Stanford University.

    Michael joined Guardant Health in 2012 as Chief Financial Officer. He is responsible for overseeing all finance and legal at the Company. Prior to joining Guardant, Michael worked as CFO at Voyage Medical, a medical device company, for over 4 years. Prior to Voyage, Michael was VP of Finance at Microchip Biotechnologies, Inc., where he led the team that raised both Series A and Series B financings for the company. Earlier in his career, Michael was a corporate attorney at Venture Law Group and acted as in-house associate counsel for Novell where he focused on intellectual property and employment issues. Prior to receiving a J.D. degree from the J. Reuben Clark Law School at Brigham Young University, Michael worked for KPMG as a tax advisor and CPA.


Guardant Health has assembled a team of world-class advisors that are trailblazers in the fields of circulating nucleic acids, personal genomics, molecular biology, clinical oncology, and information theory. The advisors listed below (and those unnamed) are instrumental in guiding the Guardant Health Management Team with the expertise required to positively disrupt oncology by bringing non-invasive cancer detection and monitoring into routine clinical practice.


Guardant Health holds a CLIA Certificate of Accreditation from the Centers for Medicare & Medicaid Services (CMS). Guardant Health also holds clinical laboratory licenses from California and other states as required by law. Please contact Guardant Health Customer Service at 855.698.8887 for copies of these licenses.

Maurice Stroun, PhD

Professor, University of Geneva



Ron Davis, PhD

Director, Stanford Genome Technology Center



Dietrich Stephan, PhD

Chairman, Dept. of Human Genetics, University of Pittsburgh


Tsachy Weissman, PhD

Professor, Information Theory, Stanford University



Pamela Kunz, MD

GI Oncologist, Stanford Cancer Center

Dave Hoon, MD

Director, Mol. Oncology,

John Wayne Cancer Institute


Jim Brooks, MD

Urologist, Stanford Cancer Institute



Michael Wiley, JD, CPA

Chief Financial Officer


Senior Management


About Us

Guardant Health is committed to positively and significantly impacting patient health through technology breakthroughs that pointedly address long-standing unmet needs in oncology. Guardant is backed by Sequoia Capital, led by a seasoned management team comprising thought leaders and successful serial entrepreneurs in next-generation sequencing and rare-cell diagnostics and is closely advised by an oncologist-led medical steering committee from leading cancer centers across North America and abroad.


Legal / Privacy